An observational study in Morbid Obesity, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-05-18.
Sponsored by Cairo University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 76 studies in Obesity, Morbid with a site in Egypt — 12 open to participants now, 16 under way, none of them phase 3. Obesity, Morbid · Egypt.
Among the 76 studies in Obesity, Morbid with a site in Egypt, this one is one of 10 that started in 2026, is one of 7 observational ones, reaches primary completion later than 6 of the 15 other live ones, and was the 65th registered.
941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.
Browse Obesity, Morbid studies →12 of the 76 studies in Obesity, Morbid with a site in Egypt are open now. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 18–45 · Women only
Cairo University · Sites in Egypt
Ages 18–65
Alexandria University · Sites in Egypt
Ages 20–60 · Healthy volunteers
Zagazig University · Sites in Egypt
Ages 18–50 · Healthy volunteers
Kafrelsheikh University · Sites in Egypt
Ages 18–65
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
76 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 3 · Phase 4 6
First in 2010; this study’s year is marked. 10 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 80 across 311 observational studies indexed under Obesity, Morbid.
Median enrollment 90 across the 69 interventional studies, 66 across the 7 observational. Of the 47 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 76 has an industry lead sponsor. The 10 most frequent:
Cairo University is the lead sponsor of 4,967 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Cairo University has 5 studies filed under Obesity, Morbid — fewer than ten, so there is no comparison to draw.
4 of the studies in Obesity, Morbid with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07397572Cairo UniversityIron Supplementation and Anemia After Sleeve Gastrectomy | 2026-11 |
| NCT07461610Cairo UniversityStool Analysis After Sleeve Gastrectomy vs Gastric Bypass | 2026-11 |
| NCT07446972Cairo UniversityImpact of Bariatric Surgery on Female Sexual Function and Sex Hormones | 2026-12 |
| NCT07289555El-Sahel Teaching HospitalTailored Stapled SADI-S: Initial Report and Preliminary Results | 2026-12-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 76 studies in Obesity, Morbid with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn whether routine stool tests can detect changes in gut function 6 months after two common types of weight loss surgery: sleeve gastrectomy and gastric bypass (including mini gastric bypass and Roux-en-Y gastric bypass). The main questions it aims to answer are:
Do stool tests show more signs of undigested food or carbohydrate malabsorption after gastric bypass compared to sleeve gastrectomy?
Do signs of gut inflammation in stool (like fecal calprotectin) decrease after surgery, and does this relate to improvements in blood sugar and weight loss?
Can simple stool test results at 6 months predict how much weight a person loses or how well their diabetes improves?
Researchers will compare stool test results between the two surgery groups (sleeve gastrectomy vs. gastric bypass) to see if the type of surgery leads to different changes in gut health.
Participants will:
Provide a stool sample before surgery and again 6 months after surgery
Provide a blood sample at the same time points to measure weight, blood sugar, and cholesterol
Undergo their planned weight loss surgery as part of their regular medical care
Background:
Obesity is a global pandemic with rising incidence, contributing significantly to morbidity, mortality, and healthcare costs worldwide. Bariatric surgery, particularly sleeve gastrectomy (SG) and gastric bypass procedures (including Mini Gastric Bypass [MGB] and Roux-en-Y Gastric Bypass [RYGB]), remains the most effective and durable treatment for morbid obesity, achieving sustained weight loss and remission of metabolic comorbidities such as type 2 diabetes.
The gastrointestinal tract, particularly the gut microbiome, has emerged as a key metabolic regulator. Obesity is associated with dysbiosis-reduced microbial diversity and altered predominance of bacterial phyla-which contributes to systemic inflammation, insulin resistance, and metabolic syndrome. Bariatric surgery induces profound and durable changes in the gut environment, including alterations in gastric emptying, intestinal transit time, bile acid signaling, and the composition of the gut microbiota.
However, advanced microbiome sequencing is expensive, time-consuming, and not readily available in many clinical settings. Routine stool analysis, by contrast, is a simple, inexpensive, and universally available test that can provide valuable preliminary data on gut health. Parameters such as stool pH, the presence of leukocytes, undigested food particles, and quantitative markers like fecal calprotectin and reducing substances can offer indirect evidence of maldigestion, mucosal inflammation, and microbial activity.
Objective:
The primary objective is to compare changes in routine stool parameters (physical examination, microscopic examination, undigested food particles, fecal calprotectin, and reducing substances) from baseline to 6 months postoperatively between patients undergoing SG and those undergoing Gastric Bypass (MGB or RYGB).
Secondary objectives include: correlating postoperative changes in stool parameters with clinical outcomes (%TWL, diabetes remission, changes in HbA1c and lipid profile); comparing the prevalence of specific stool findings between groups; evaluating whether baseline stool parameters can predict postoperative outcomes; and assessing the utility of routine stool analysis as a simple, low-cost tool for monitoring gut health after bariatric surgery.
Methods:
This is a prospective, two-arm, observational cohort study conducted at the Department of General Surgery, Kasr Al-Ainy University Hospitals, Cairo, Egypt. The study period is from March 2026 to December 2026.
Study Timeline and Data Collection:
Patients will be assessed at two predefined time points:
T0 (Baseline): 1-2 weeks preoperatively - informed consent, demographic data, medical history, anthropometric measurements, blood samples, stool sample
T1 (6 months): 6 months ± 2 weeks postoperatively - anthropometric measurements, blood samples, stool sample, assessment of comorbidities, final outcomes
Clinical and Anthropometric Measurements:
Body weight (kg) and height (m) for BMI calculation (kg/m²)
Percentage total weight loss (%TWL) at 6 months = [(initial weight - 6-month weight) / initial weight] × 100
Presence and status of comorbidities (diabetes, hypertension, dyslipidemia)
Diabetes remission defined as HbA1c \< 6.5% off all antidiabetic medications at 6 months
A total of 46 patients with morbid obesity (BMI ≥40 or ≥35 kg/m² with comorbidities) scheduled for primary laparoscopic bariatric surgery will be enrolled and allocated into two groups: Group A (SG, n=23) and Group B (Gastric Bypass [MGB or RYGB], n=23). The type of gastric bypass (MGB vs. RYGB) will be determined by the surgical team based on patient anatomy, comorbidities, and surgeon preference, reflecting real-world clinical practice.
Blood Sampling and Biochemical Analysis:
After an overnight fast (8-12 hours), venous blood will be collected at both time points for:
Stool Sample Collection and Analysis:
Patients will be provided with a sterile, leak-proof stool collection container and written instructions. They will collect a fresh morning stool sample at home. Samples should be transported to the hospital laboratory within 2 hours of collection. If immediate transport is not possible, samples should be refrigerated (4°C) and transported within 12 hours.
Stool analysis parameters include:
Physical Examination: Color, consistency, odor, mucus, pH
Microscopic Examination: White Blood Cells (WBCs), Red Blood Cells (RBCs), trophozoites, cysts, ova, larva, flagellates, ciliate
Undigested Food Particles: Meat fibers, vegetable particles, starch granules, fat globules
Quantitative Tests: Fecal calprotectin (ELISA), Reducing substances (Clinitest tablets)
Patients with morbid obesity scheduled for primary bariatric surgery at Kasr Al-Ainy University Hospitals, Cairo, Egypt.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergoing primary laparoscopic sleeve gastrectomy as treatment for morbid obesity. This group serves as the restrictive procedure comparator.
Procedure: Laparoscopic Sleeve Gastrectomy
Patients undergoing primary laparoscopic gastric bypass, including both Mini Gastric Bypass (MGB) and Roux-en-Y Gastric Bypass (RYGB), as treatment for morbid obesity. This group serves as the diversionary procedure comparator.
Procedure: Mini Gastric Bypass · Procedure: Roux-en-Y Gastric Bypass
Laparoscopic sleeve gastrectomy performed using a standard technique with a 36-Fr bougie, transecting the stomach starting 4-6 cm from the pylorus, excising the entire greater curvature and fundus. The staple line is inspected for hemostasis and leakage.
Laparoscopic mini gastric bypass performed using a standard technique with a long gastric tube created from the angle of His to the antrum, and a loop gastrojejunostomy with a biliopancreatic limb of 200 cm.
Laparoscopic Roux-en-Y gastric bypass performed using a standard antecolic, antegastric technique. A small 30-mL gastric pouch is created. The biliopancreatic limb is 70-150 cm, and the alimentary (Roux) limb is 100-150 cm. Jejunojejunostomy is performed to restore continuity.
Change in Stool pH
Change in stool pH measured by pH indicator strip from preoperative baseline to 6 months after surgery. Comparison will be made between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.
Time frame: At Baseline and at 6 months postoperatively
Change in Fecal Calprotectin Level
Change in fecal calprotectin concentration (μg/g) measured by ELISA from preoperative baseline to 6 months after surgery. Comparison will be made between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.
Time frame: At Baseline and at 6 months postoperatively
Presence of Undigested Food Particles
Presence or absence of undigested meat fibers and vegetable particles on microscopic examination at 6 months after surgery. Comparison of prevalence between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.
Time frame: At Baseline and at 6 months postoperatively
Presence of Reducing Substances
Presence or absence of reducing substances (indicating carbohydrate malabsorption) measured by Clinitest tablets at 6 months after surgery. Comparison of prevalence between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.
Time frame: At Baseline and at 6 months postoperatively
Change in Stool White Blood Cell Count
Change in white blood cell count (cells per high-power field) on microscopic examination from preoperative baseline to 6 months after surgery. Comparison will be made between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.
Time frame: At Baseline and at 6 months postoperatively
Change in Stool Red Blood Cell Count
Change in red blood cell count (cells per high-power field) on microscopic examination from preoperative baseline to 6 months after surgery. Presence of RBCs may indicate mucosal irritation at staple lines or altered barrier function. Comparison will be made between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.
Time frame: At Baseline and at 6 months postoperatively
Percentage Total Weight Loss (%TWL)
Percentage total weight loss calculated as \[(initial weight - 6-month weight) / initial weight\] × 100. Comparison between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.
Time frame: 6 months postoperatively
Diabetes Remission Rate
Proportion of patients with type 2 diabetes at baseline who achieve remission, defined as HbA1c \< 6.5% off all antidiabetic medications at 6 months postoperatively. Comparison between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.
Time frame: 6 months postoperatively
Change in Fasting Plasma Glucose
Change in fasting plasma glucose (mg/dL) from preoperative baseline to 6 months after surgery
Time frame: At Baseline and at 6 months postoperatively
Change in HbA1c
Change in glycated hemoglobin (HbA1c %) from preoperative baseline to 6 months after surgery.
Time frame: At Baseline and at 6 months postoperatively
Change in Lipid Profile
Changes in total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides (mg/dL) from preoperative baseline to 6 months after surgery.
Time frame: At Baseline and at 6 months postoperatively
Change in High-Sensitivity C-Reactive Protein (hs-CRP)
Change in hs-CRP (mg/L) from preoperative baseline to 6 months after surgery as a marker of systemic inflammation.
Time frame: At Baseline and at 6 months postoperatively
Correlation Between Stool Parameters and Clinical Outcomes
Correlation between changes in stool parameters (WBC count, RBC count, pH, fecal calprotectin, reducing substances, undigested food particles, mucus, trophozoites, cysts, ova, larva, flagellates, ciliates) and clinical outcomes (%TWL, change in HbA1c) using Spearman's rank correlation coefficient.
Time frame: 6 months postoperatively
Prevalence of Elevated Fecal Calprotectin
Prevalence of elevated fecal calprotectin (\>50 μg/g) in each group at baseline and 6 months postoperatively. Comparison between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.
Time frame: At Baseline and at 6 months postoperatively
Prevalence of Positive Reducing Substances
Prevalence of positive reducing substances (indicating carbohydrate malabsorption) in each group at baseline and 6 months postoperatively. Comparison between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.
Time frame: At Baseline and at 6 months postoperatively
Prevalence of Mucus in Stool
Prevalence of visible mucus on physical examination in each group at baseline and 6 months postoperatively. Comparison between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.
Time frame: At Baseline and at 6 months postoperatively
Prevalence of Elevated White Blood Cells in Stool
Prevalence of elevated white blood cells (\>10 per high-power field) on microscopic examination in each group at baseline and 6 months postoperatively. Comparison between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.
Time frame: At Baseline and at 6 months postoperatively
Prevalence of Elevated Red Blood Cells in Stool
Prevalence of elevated red blood cells (\>5 per high-power field) on microscopic examination in each group at baseline and 6 months postoperatively. Comparison between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.
Time frame: At Baseline and at 6 months postoperatively
Prevalence of Trophozoites in Stool
Prevalence of trophozoites (any) on microscopic examination in each group at baseline and 6 months postoperatively. Comparison between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.
Time frame: At Baseline and at 6 months postoperatively
Prevalence of Cysts in Stool
Prevalence of cysts (any) on microscopic examination in each group at baseline and 6 months postoperatively. Comparison between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.
Time frame: At Baseline and at 6 months postoperatively
Prevalence of Ova in Stool
Prevalence of ova (any) on microscopic examination in each group at baseline and 6 months postoperatively. Comparison between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.
Time frame: At Baseline and at 6 months postoperatively
Prevalence of Larva in Stool
Prevalence of larva (any) on microscopic examination in each group at baseline and 6 months postoperatively. Comparison between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.
Time frame: At Baseline and at 6 months postoperatively
Prevalence of Flagellates in Stool
Prevalence of flagellates (e.g., Giardia) on microscopic examination in each group at baseline and 6 months postoperatively. Comparison between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.
Time frame: At Baseline and at 6 months postoperatively
Prevalence of Ciliates in Stool
Prevalence of ciliates (e.g., Balantidium coli) on microscopic examination in each group at baseline and 6 months postoperatively. Comparison between Sleeve Gastrectomy (SG) and Gastric Bypass (MGB/RYGB) groups.
Time frame: At Baseline and at 6 months postoperatively
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Nov 2026, 7 months after the start.
Of 138 non-industry observational studies under Obesity, Morbid, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 132. This study's planned 7 months is below that.
Counting every sponsor, half of 139 studies reached it within 46 months; a quarter within 16 and three quarters within 132.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.